87,160 Shares in Pfizer Inc. (NYSE:PFE) Acquired by Maxi Investments CY Ltd

Key Points

• Maxi Investments CY Ltd acquired 87,160 shares of Pfizer Inc. (NYSE:PFE), valued at approximately $2,209,000, as per its recent SEC filing.
• A significant portion, 68.36%, of Pfizer's stock is owned by hedge funds and other institutional investors, highlighting strong institutional interest in the company.
• Research analysts show mixed sentiment towards Pfizer, with a consensus rating of "Moderate Buy" and target prices ranging from $25.00 to $32.00.

Maxi Investments CY Ltd bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 87,160 shares of the biopharmaceutical company's stock, valued at approximately $2,209,000.

A number of other large investors have also recently made changes to their positions in PFE. Clarity Asset Management Inc. acquired a new position in Pfizer in the fourth quarter valued at approximately $27,000. Gould Capital LLC boosted its holdings in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. North Capital Inc. acquired a new position in Pfizer in the first quarter valued at approximately $28,000. Bayforest Capital Ltd acquired a new position in Pfizer in the first quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in Pfizer in the fourth quarter valued at approximately $30,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PFE has been the subject of a number of research analyst reports. Morgan Stanley upped their price target on Pfizer from $31.00 to $32.00 and gave the company an "equal weight" rating in a report on Wednesday, April 30th. Berenberg Bank lowered their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Bank of America increased their price objective on Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Wolfe Research increased their price objective on Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a report on Wednesday, April 30th. Finally, BMO Capital Markets decreased their price objective on Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $28.28.

Pfizer Trading Up 0.3%

NYSE:PFE opened at $23.56 on Tuesday. The stock has a fifty day moving average price of $24.37 and a two-hundred day moving average price of $24.53. The stock has a market capitalization of $133.95 billion, a price-to-earnings ratio of 17.07, a PEG ratio of 0.85 and a beta of 0.52. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.3%. Pfizer's dividend payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.